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Thank you for your interest in our case report and discussion.1 Pulmonary fibrosis 
arising in association with methotrexate therapy was first reported in the 1970s in the 
context of cancer chemotherapy with very high doses given (up to 3.5g/m2). Such 
patients accumulated a very high dose e.g. 41g over a few weeks.2 In this specific 
This is the peer reviewed version of the following article: Affleck, A., et al. "Lungs, methotrexate 
and psoriasis: reply from author", Clinical and Experimental Dermatology (2019), which has been 
published in final form at https://doi.org/10.1111/ced.13994. This article may be used for non-
commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
This article is protected by copyright. All rights reserved.
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clinical scenario it is possible that methotrexate was causative although interestingly, 
the same author comments a year later that there are often many confounding 
factors e.g. use of concomitant agents which may also have pulmonary toxicity. They 
state, in practice, cytotoxic drug-induced lung disease may be difficult to establish 
with certainty because other potential causes of pulmonary disease are frequently 
present.3 Experimental mouse models have shown that administration of very high 
daily doses of methotrexate (3mg/kg) for 5 weeks causes pulmonary fibrosis.4 
However, again, this is quite different from the low weekly doses of methotrexate 
given for psoriasis in clinical practice. Direct extrapolation from both these examples 
is not possible. Also, it should be emphasised that many apparent case reports of 
“pulmonary fibrosis” arising in the context of methotrexate treatment for psoriasis are 
in fact spurious including your reference 6 in which Karadag et al describe a case of 
resolving interstitial pneumonitis NOT fibrosis. With regards to the Japanese 
populations alluded to with psoriasis and interstitial pneumonia (IP) it is with interest 
that the prevalence of IPs is greater than the background prevalence of the most 
common form of chronic IP which is idiopathic pulmonary fibrosis (IPF).5 Regarding 
our patient, we suggest that there were 2 possibilities –  
1. There was no connection between his psoriasis and interstitial lung disease; 
the apparent correlation was a coincidence. 
2. There was a correlation between his psoriasis and interstitial lung disease in 
that both disorders shared underlying immunological pathways.  
 
The same argument applies to the role of methotrexate in interstitial lung disease 
(ILD); active role or innocent bystander? We do not believe that methotrexate had 
any negative effect on the natural history of the ILD. Correlation does not prove 
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causation.  We agree that there may be a group of patients with psoriasis who are at 
increased risk of developing ILD and identifying these individuals is desirable.  
However, at the present time we do not believe that routine chest CT scanning is 
indicated nor any blind preventative medical treatments both of which may have 
side-effects. Further discussion and debate is desirable. 
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